ArticleCNS neuroscience & therapeutics2026
Synergistic Interaction Between MALAT1/miR-30b-5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab-Refractory NMOSD.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveDespite achieving complete peripheral B cell deletion after over 6 months of rituximab therapy, a clinically significant minority of neuromyelitis optica spectrum disorder (NMOSD) patients experience breakthrough relapses, yet the underlying mechanism remains unclear. Our study aims to explore the underlying mechanism-the contribution of the MALAT1/miR-30b-5p/BAFF axis activation in monocytes to NMOSD disease attacks and relapses resistant to rituximab therapy.
methodsTo investigate immune dysregulation in NMOSD, we established clinical groups comprising peripheral blood mononuclear cells (PBMCs) and serum from NMOSD patients: onset cases (PBMCs: n = 10; serum: n = 23) and rituximab-treated cases subdivided into remission (n = 26) and rituximab-refractory relapse (n = 13), along with healthy controls (n = 15). To profile the MALAT1/miR-30b-5p/BAFF axis and inflammatory mediators, we quantified MALAT1, miR-30b-5p, BAFF, and cytokine levels using qPCR, ELISA, and Western Blot and validated molecular interactions via dual-luciferase reporter assays. To characterize cellular heterogeneity, single-cell RNA sequencing (scRNA-seq) was performed on PBMCs from two rituximab-refractory relapsed NMOSD patients, two rituximab-remission NMOSD patients, and two healthy controls. For mechanistic validation, THP-1 cells were transfected with MALAT1 overexpression constructs or miR-30b-5p mimics, followed by functional assessments to determine their roles in monocyte activation and cytokine production.
resultsSignificant activation of the MALAT1/miR-30b-5p/BAFF axis was observed in NMOSD patients at disease onset compared to healthy controls. Moreover, this axis correlated with rituximab-refractory NMOSD, featuring monocyte-specific MALAT1 upregulation and elevated serum BAFF in rituximab-refractory relapse patients. In THP-1 cells, the overexpression of MALAT1 downregulated miR-30b-5p, resulting in increased BAFF expression and pro-inflammatory cytokines secretion (IL-1β, IL-8, TNF-α), while also accelerating cell proliferation. Significantly, transfection with miR-30b-5p mimics reversed the MALAT1-driven upregulation of BAFF and pro-inflammatory cytokines, supporting the MALAT1/miR-30b-5p/BAFF axis as a regulatory circuit underlying inflammatory dysregulation in NMOSD.
conclusionWe identify the MALAT1/miR-30b-5p axis as a driver of NMOSD pathogenesis and rituximab-refractory relapse. Upregulation of monocytic MALAT1 suppresses miR-30b-5p, leading to increased BAFF and pro-inflammatory cytokines secretion, thereby promoting inflammatory responses. Targeting this pathway may offer therapeutic potential for relapse prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.